Clinical trial · Interventional
Camrelizumab Combined With AVD in the First-line Treatment for Patients With Advanced Classical Hodgkin's Lymphoma
Single-arm, Multi-center and Phase II Clinical Trial of Camrelizumab Combined With AVD (Epirubicin, Vincristine and Dacarbazine) in the First-line Treatment for Patients With Advanced Classical Hodgkin's Lymphoma
NCT04067037CI-TRIAL-00102169active not recruitingPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a prospective single-arm, multi-center and phase II clinical trial to observe the efficacy and safety of Camrelizumab combined with AVD in the first-line treatment for patients with advanced classical Hodgkin's lymphoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Classical Hodgkin Lymphoma | Classic Hodgkin Lymphoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Camrelizumab | Drug | Camrelizumab | ALIAS |
| Dacarbazine | Drug | Dacarbazine | ALIAS |
| Epirubicin | Drug | Epirubicin | ALIAS |
| Vincristine | Drug | Vincristine | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Camrelizumab Combined With AVD regimen
- description
- Camrelizumab 200mg, Intravenous administration on day 1 and day 15 combined with regimen：AVD (Epirubicin, Vincristine and Dacarbazine): repeated every 4 weeks, up to 6 cycles.
- interventionNames
- Drug: Camrelizumab
- Drug: Epirubicin
- Drug: Vincristine
- Drug: Dacarbazine
Primary outcomes (1)
- measure
- complete metabolic response rate (CMRR)
- timeFrame
- every 8 weeks from the day of the first cycle of treatment to 4 weeks after the completion of 6 cycles of treatment after the last patient's enrollment (each cycle is 28 days)
- description
- the proportion of patients who achieved a complete metabolic response (CMR) as their best overall response (BOR) from the first dose of study treatment through the end-of-treatment (EOT) assessment
Secondary outcomes (5)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age between 18 to 75 years old (including 18 and 75) 2. Diagnosed as advanced classical hodgkin's lymphoma based on histopathology 3. Subjects must be untreated (Ann Arbor Stage III/IV or Ann Arbor II with B symptoms along with mediastinal big tumor or extranodal changes) 4. No receiving chemotherapy before enrollment 5. Having at least one measurable lesions 6. World health organization-Eastern Cooperative Oncology Group Performance Status (ECOG) 0-2 7. Life expectancy no less than 3 months 8. enough main organ function 9. Pregnancy test within 7 days must be negative for women of childbearing period, and appropriate measures should be taken for contraception for women in childbearing period during the study and six months after this study 10. Agreeing to sign the written informed consents Exclusion Criteria: 1. Diagnosed as nodular lymphocyte predominant lymphoma or grey-zone lymphoma 2. Diagnosed as central nervous system lymphoma 3. usage of immunosuppressants before enrollment and the dose of immunosuppressant used \>10mg / day oral prednisone for more than 2 weeks 4. Previously treated with anti-PD-1/PD-L1/PD-L2/CTLA-4 5. Active autoimmune disease 6. Vaccination with anti-tumor vaccine or other immune treatments less than 3 months 7. Serious surgery and trauma less than two weeks 8. Other malignant tumor history or active malignant tumor need be treated 9. Systemic therapy for serious acute/chronic infection 10. Congestive heart failure, uncontrolled coronary heart disease, arrhythmia and heart infarction less than 6 months 11. Active tuberculosis 12. Vaccination with live attenuated vaccine less than 4 weeks 13. HIV-positive, AIDS patients and untreated active hepatitis 14. Researchers determine unsuited to participate in this trial
References
Publications (0)
Data not yet available
No reference posted for this study.